Comparing Stevanato Group (NYSE:STVN) & iCAD (NASDAQ:ICAD)

Stevanato Group (NYSE:STVN) and iCAD (NASDAQ:ICAD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

24.6% of iCAD shares are held by institutional investors. 0.7% of Stevanato Group shares are held by insiders. Comparatively, 12.0% of iCAD shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Stevanato Group and iCAD’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	$1.17 billion	N/A	$157.62 million	€0.55 ($0.60)	35.53
iCAD	$17.32 million	2.05	-$4.85 million	($0.12)	-11.17

Stevanato Group has higher revenue and earnings than iCAD. iCAD is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Stevanato Group has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Stevanato Group and iCAD, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0	2	4	0	2.67
iCAD	0	0	0	0	N/A

Profitability

This table compares Stevanato Group and iCAD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stevanato Group	12.57%	12.61%	7.25%
iCAD	-15.20%	-14.00%	-10.32%

Summary

Stevanato Group beats iCAD on 8 of the 11 factors compared between the two stocks.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

About iCAD

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.